Senores Pharma Q1 Results FY27: Net Profit at Rs 30 Cr for June 2026 Quarter

Key Takeaways

• Senores Pharma's revenue for the June 2026 quarter came in at Rs 180 Cr, rose 30.60% year on year from Rs 137 Cr.
• Senores Pharma came in at a consolidated net profit of Rs 30 Cr, up 43.77% from Rs 21 Cr in Q1 FY26.
• Gross profit was reported at Rs 43 Cr for the quarter.
• The stock traded at Rs 1,323 on 27 July 2026, down 6.32% during the session.

Senores Pharma's Q1 results FY27 revenue came in at Rs 180 Cr for the quarter ended 30 June 2026, rose 30.60% year on year from Rs 137 Cr. The company came in at a consolidated net profit of Rs 30 Cr, up 43.77% from Rs 21 Cr in Q1 FY26 on a consolidated basis. This article answers the key questions on the Senores Pharma Q1 results FY27 directly: how revenue and profit moved, what drove the change, and how the stock reacted, before covering what investors should track from here.

Prepared by Kunal Singla, Associate Director at Univest, this review of the Senores Pharma Q1 results FY27 is based on figures disclosed in the company's exchange filing for the June 2026 quarter.

Click Here – Get Free Investment Predictions

Senores Pharma Q1 Results FY27: Key Numbers at a Glance

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 180 Cr	Rs 137 Cr	30.60%
Gross Profit	Rs 43 Cr	Rs 28 Cr	55.56%
Net Profit	Rs 30 Cr	Rs 21 Cr	43.77%

All figures in the Senores Pharma Q1 results FY27 table above are on a consolidated basis for the quarter ended 30 June 2026, compared with Q1 FY26.

Senores Pharma Q1 Results FY27: What Drove Revenue

Revenue for Senores Pharma in Q1 FY27 rose 30.60% from Rs 137 Cr to Rs 180 Cr, against Rs 137 Cr in Q1 FY26. As a company in the pharmaceutical formulations and exports space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.

Senores Pharma Q1 Results FY27: Profitability Breakdown

Senores Pharma came in at a consolidated net profit of Rs 30 Cr, up 43.77% from Rs 21 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 43 Cr, a change of 55.56% from Rs 28 Cr in Q1 FY26.

The broadly consistent movement between gross profit and net profit in the Senores Pharma Q1 results FY27 suggests the quarter's profit performance is being driven mainly by core operations rather than one-off or below-the-line items.

Stock Price Reaction to the Senores Pharma Q1 Results FY27

Senores Pharma shares traded at Rs 1,323 on 27 July 2026, down 6.32% during the session. This reaction reflects how the market weighed the revenue and profit numbers together, alongside broader market conditions on the day.

Talk to a SEBI Registered Investment Adviser Before You Invest

What the Senores Pharma Q1 Results FY27 Mean for Investors

The Senores Pharma Q1 results FY27 give investors three concrete data points: a revenue base of Rs 180 Cr, a net profit of Rs 30 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.

Comparing this quarter with peers in the pharmaceutical formulations and exports space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Senores Pharma Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.

Business Context Behind the Senores Pharma Q1 Results FY27

Senores Pharmaceuticals operates in the pharmaceutical formulations and exports space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Senores Pharma Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.

Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Senores Pharma Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.

Key Things to Watch After the Senores Pharma Q1 Results FY27

• Sequential trend: Whether the momentum in the Senores Pharma Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.
• Management commentary: Guidance on demand, margins and capital allocation for the rest of FY27.
• Sector conditions: Developments in the pharmaceutical formulations and exports space that could influence input costs, pricing power or competitive intensity.
• Corporate actions: Any dividend, capex or strategic announcements accompanying the results that signal management's confidence in the outlook.
• Balance sheet health: Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Senores Pharma has to fund future growth.

Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.

Conclusion

The Senores Pharma Q1 results FY27 show consolidated revenue of Rs 180 Cr and a net profit of Rs 30 Cr for the quarter ended 30 June 2026. The quarter's profit delivery keeps the near-term earnings narrative broadly intact. As Kunal Singla notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.

FAQs on Senores Pharma Q1 Results FY27

What was Senores Pharma's revenue in Q1 results FY27?

Ans. Senores Pharma's revenue in Q1 results FY27 was Rs 180 Cr, rose 30.60% year on year from Rs 137 Cr.

What was Senores Pharma's net profit in Q1 results FY27?

Ans. Senores Pharma's net profit in Q1 results FY27 was Rs 30 Cr on a consolidated basis for the quarter ended 30 June 2026.

What was Senores Pharma's gross profit in Q1 FY27?

Ans. Senores Pharma's gross profit in Q1 results FY27 was Rs 43 Cr, against Rs 28 Cr in Q1 FY26.

When were the Senores Pharma Q1 results FY27 announced?

Ans. The Senores Pharma Q1 results FY27 were announced on 27 July 2026, covering the quarter ended 30 June 2026.

How did Senores Pharma shares react to the Q1 results FY27?

Ans. Senores Pharma shares traded at Rs 1,323 on 27 July 2026, down 6.32% following the Q1 results FY27.

Were the Senores Pharma Q1 results FY27 consolidated or standalone?

Ans. The Senores Pharma Q1 results FY27 are on a consolidated basis, as reported in the company's exchange filing for the June 2026 quarter.

What should investors watch after Senores Pharma's Q1 results FY27?

Ans. Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the pharmaceutical formulations and exports space, and any corporate action announcements.

Are the Senores Pharma Q1 results FY27 a buy signal?

Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.